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Abstract Monogenic diabetes constitutes a heterogeneous
group of single gene disorders. The molecular background
and clinical picture of many of these diseases have been
described. While each of these forms is much less prevalent
than multifactorial type 1 and type 2 diabetes mellitus
(T2DM), together they affect millions of patients world-
wide. Genetic diagnosis, which has become widely avail-
able, is of great clinical importance for patients with single
gene diabetes. It helps to fully understand the pathophysiol-
ogy of the disease, tailor the optimal hypoglycemic treat-
ment, and define the prognosis for the entire family.
Monogenic diabetes forms can be divided into 2 large
groups, resulting from impaired insulin secretion or from
an abnormal response to insulin. There are several lessons
we have been taught by single-gene diabetes. We learned
that the gene responsible for the occurrence of diabetes can
be identified if an appropriate search strategy is used. In
addition, discoveries of genes responsible for monogenic
disorders pointed to them as susceptibility candidates for
T2DM. Moreover, establishing that some families of proteins
or biological pathways, such as transcription factors or potas-
sium channel subunits, are involved in monogenic diabetes
sparked research on their involvement in multifactorial diabe-
tes. Finally, the example of single gene diabetes, particularly
HNF1A MODY and permanent neonatal diabetes associated
with the KCNJ11 and ABCC8 genes, all efficiently controlled
on sulfonylurea, inspires us to continue the efforts to tailor
individual treatment for T2DM patients. In this review paper,
we summarize the impact of single gene disease discoveries
on diabetes research and clinical practice.
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Introduction
Physicians and researchers have been aware of diabetes
mellitus heterogeneity for many decades. They well under-
stood that hyperglycemia was just a common feature for a
group of distinct disorders with different pathophysiology.
First, they learned to distinguish the 2 most prevalent dia-
betic phenotypes–type 1 diabetes mellitus (T1DM), and
type 2 diabetes mellitus (T2DM) [1, 2]. As soon as in the
1960s and 1970s, some experts realized that medicine was
dealing with an even larger complexity of diabetes etiolo-
gies [3]. It was observed that in some families, the disease
corresponded to neither insulin-dependent (T1DM), nor
non-insulin-dependent (T2DM) diabetes. The affected indi-
viduals presented some features of both of the major diabe-
tes forms, such as young age of onset and lack of obesity on
the one hand, and clinical insulin independence on the other.
This observation led to the description of the first monogen-
ic forms of diabetes, maturity onset diabetes of the young
(MODY) [4, 5]. Over the last decades more such monogenic
forms of diabetes have been described [6–8]. It was also
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revealed that while each of these single gene diabetes forms
were rare, they were numerous and, together, created a
complex pathophysiological and clinical picture.
Beginning from the early 1990s, discovering the mo-
lecular background of monogenic disorders, including
diabetes, became almost a routine procedure [9]. Thus,
substantial progress was made in the dissection of the
genetic background of monogenic forms of diabetes.
The common denominators of these disorders are hyper-
glycemia and the occurrence of a severe single-gene
mutation that causes the disease phenotype. Subsequent-
ly, it was possible to establish the specific diagnosis
through the analysis of the patient’s DNA sequence.
However, there are also substantial differences between
these monogenic disorders. For example, based on path-
ophysiology, they may be divided into 2 major groups—
associated with either beta cell defect or with severe insulin
resistance (Table 1) [8, 10]. They also vary in respect of
mode of inheritance, including autosomal dominant, au-
tosomal recessive, and maternally inherited forms. Nev-
ertheless, even in diseases with the same mode of
inheritance interesting differences are observed, as in
MODY families diabetes is passed from one generation
to the other, while in permanent neonatal diabetes mel-
litus (PNDM) we observed many cases with spontaneous
mutations [11]. These monogenic disorders are character-
ized by different ages of disease onset, from infants in
PNDM, through adolescents in MODY, to middle aged
subjects in some laminopathies [5, 8, 10, 11]. There are
also substantial differences in their prevalence. For ex-
ample, it is estimated that the proportion of MODY patients
may constitute about 1 % of all diabetic cases, which would
correspond to half a million patients on the European conti-
nent alone [12]. On the other hand, PNDM is very rare, it
affects 1 child in 250 000 live births [11].
Almost half a century of successful research constitutes
an excellent perspective to look at what the single gene
diabetes forms have taught us.
Gene Search and Discovery
One important lesson that we learned from single gene
diabetes is that the gene responsible for the occurrence of
diabetes can be identified if appropriate methodology is
used. The successful identification of monogenic diabetes
genes encouraged and accelerated the genetic studies in
T2DM. In general, there were 2 strategies used for the
search for monogenic diabetes in the late 1980s and
1990s. The first one was the candidate gene approach,
focused on a limited set of genes picked up for the mutation
search based on their role in insulin secretion or insulin
action. This strategy led to the discovery of the first mono-
genic diabetes genes—for example insulin receptor and
glucokinase [13, 14]. It soon became clear that a more
systematic strategy was necessary to increase the effica-
cy and success rate of the search for new genes. The
strategy called genome-wide linkage study with subse-
quent positional cloning which led to the identification
of the HNF4A and HNF1A genes, which were found to
be responsible for 2 forms of monogenic diabetes, initially
called MODY1 and MODY3, respectively [15, 16]. This
discovery pointed to the entire family of transcription factors,
leading to further single gene disorder discoveries, which
involved HNF1B, IPF, NEUROD1, and some other genes
[17–19].
The search for complex, common T2DM followed this
general scheme seen in monogenic diseases. However, in
polygenic diseases, scientists were looking for the associat-
ed susceptibility alleles with modest effect, rather than for
sequence differences with strong causal effects. Although
some sequence differences were identified as increasing the
risk of T2DM using candidate gene association study de-
sign, for example the Pro12Ala variant of the PPARG gene,
and the Glu23Lys of the KCNJ11 gene [20, 21], this strategy
brought many more disappointments than successes. Thus,
as for monogenic diabetes, a more systematic strategy be-
came desirable. Initially, researchers employed the same
scheme of genome-wide linkage studies with subsequent
positional cloning [22]. As, unlike in monogenic disorders,
extended pedigrees were not available, large collections of
small families were genotyped [22, 23]. Unfortunately, this
strategy generated a significant amount of inconclusive data,
unconfirmed findings, and, in general, was not successful.
The only T2DM gene identified by this combined approach
was TCF7L2, a transcription factor involved in the insulin
secretion process [24]. The solution came together with
high-throughput efficient genotyping methodology and a
Table 1 Select important steps in unraveling genetic heterogeneity of
monogenic diabetes
Beta cell disease Insulin resistance
Year Disease Year Disease





1988 Type A insulin
resistance
1992 MIDD 1988 Donohue syndrome
1998 Wolfram syndrome 2000 Familial partial
lipodystrophy




2007 Insulin related PNDM
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new generation of whole-genome search methods—genome
wide association studies (GWAS) [25]. This systematic ap-
proach created a breakthrough and led to the identification
of several dozens of genes whose variants confer small
effect on T2DM susceptibility [26].
After the first set of single gene diabetes types was
described in the 1990s, some researchers postulated that
the possible involvement of these genes in common
multifactorial forms of the disease should be tested.
The hypothesis assumed that if a gene had been shown
to carry a causal variant for monogenic diabetes with
high penetrance, it may also include other variants with
a detectable effect on T2DM. These variants could have
an influence on gene expression or function with their
impact being much too low to result in Mendelian
disease inheritance but sufficient to modify the risk of
a polygenic disease. Such small effect could be detected
by case-control association studies. Not surprisingly, the
initial studies were based on the candidate-gene strategy
and involved genes identified as linked to MODY
(HNF1A, HNF4A, glucokinase), PNDM (KCNJ11,
ABCC8), and severe forms of insulin resistance
(PPARG) [20, 27]. This phase of research was then
followed by GWAS, which confirmed some of the ear-
lier findings and added some new variants in monogenic
diabetes genes associated with T2DM [26]. The list of
genes responsible for monogenic forms of diabetes and
associated with an increased risk of T2DM in GWAS is
presented in Table 2.
GWAS identified many loci associated with the risk
of T2DM and metabolic traits, such as obesity [26]. In
spite of this substantial progress, the genetic loci so far
identified are responsible for only a small portion of the
overall genetic heritability of T2DM [28]. In addition,
taken together, genetic risk markers have very limited
application in individual risk prediction [29]. One of the
new areas in the search is the identification of low-
frequency, intermediate penetrance, moderate to large
effect variants [30].
Whole genome sequencing or exome sequencing are
novel approaches based on next generation sequencing
[31]. They found application as a diagnostic tool,
screening method for monogenic disorders and complex
diseases [32]. Exome sequencing in diabetes and other
common diseases reflects a paradigm shift in contempo-
rary genetic studies: according to the novel hypothesis,
T2DM and other polygenic disorders develop on a
complex background of multiple rare variants with mod-
erate to high impact on phenotype and variable pene-
trance, which obscures underlying Mendelian inheritance
[33•]. This suggests that monogenic disorders might be
pathogenetically closer to T2DM than it was previously
perceived. Genes harboring mutations causative for
monogenic diabetes are likely to contain low frequency
causal variants in T2DM.
Single Gene Diabetes Pathways and T2DM
Rare monogenic forms of diabetes with a single and
well defined molecular cause help trace links between
faulty genes, biochemical or regulatory dysfunction, and
clinical phenotype. These forms can be considered sim-
plified and partial models of T2DM, although, they
cannot replicate the complexity of its pathogenesis.
The process of insulin secretion is a particularly good
illustration of how monogenic models help to under-
stand the pathophysiology of T2DM. Glucose is trans-
ported inside pancreatic beta cells via several transporters and
undergoes phosphorylation by the enzyme glucokinase, a
specific form of hexokinase characterized by a low affin-
ity to glucose and lack of inhibition by the product of
catalyzed reaction, glucose-6-phosphate [34, 35]. The
activated glucose enters glycolysis, the tricarboxylic ac-
id cycle, and provides energy for adenosine triphosphate
(ATP) synthesis in mitochondria through oxidative phos-
phorylation. The specific kinetic features of glucokinase,
the gatekeeper of ATP synthesis process, make the
amount of the ATP produced fairly proportional to the
glucose concentration outside the beta cell. When the
glucose level is low, the concentration of ATP remains
low and ATP-sensitive potassium channels in the beta
cell plasmatic membrane remain open. Potassium ion
influx in the cell maintains the membrane potential.
Increased glucose availability results in increased ATP
concentration, closure of the ATP-gated channels, and
activation of voltage-gated calcium channels. The influx
of calcium in the cell signals for exocytosis of insulin
granules [36].
Table 2 Variants within “monogenic diabetes” genes associated with
T2DM—either identified or confirmed by large scale association
studies
Locus Chromosome Monogenic phenotype T2DM-
associated
variant
PPARG 3 Insulin resistance syndrome Pro12Ala
KCNJ11 11 PNMD, TNDM, MODY Glu23Lys
ABCC8 11 PNMD, TNDM, MODY Ala369Ser
HNF1B 17 HNF1B MODY rs3110641
WFS1 4 Wolfram syndrome rs10010131,
rs6446482
HNF1A 12 HNF1A MODY rs7957197
GCK 7 GCK MODY, PNDM rs1799884
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Nearly every step of this process can be linked to a
monogenic model of diabetes. Mutations affecting GLUT2,
one of the glucose transporters in the human beta cells,
result in the Fanconi-Bickel syndrome. This is a phenotyp-
ically complex glycogen storage disease with postprandial
hyperglycemia or overt diabetes. Abnormal hepatic glucose
clearance seems to be the major mechanism of hyperglyce-
mia [37]. Impaired glucose sensing by beta cells also plays a
significant role [38]. Recently, some very rare cases of
PNDM have been linked to the mutations altering GLUT2
[39]. The finding that patients with homozygous mutations
of the gene encoding GLUT2 develop neonatal diabetes
suggests that this transporter plays an important role in the
physiology of the beta cell. Loss of function mutations in
GCK, a gene coding for glucokinase, result in a mild form of
MODY [14]. The glucose sensing role of the affected gene
product implies an intriguing phenotype: the blood glucose
threshold for insulin secretion is increased, but the function-
al capacity of beta cells is preserved; a rightward shift of the
dose-response curve is observed [40]. In addition, in a very
rare biallelic inactivation of GCK, a phenotype of PNDM is
observed: a complete loss of the capacity to respond to
elevated glucose results in a phenotype of very early onset
severe diabetes [41]. The next step in beta cell response to
glucose, which is ATP synthesis, is impaired in a monogenic
disease affecting mitochondria—maternally inherited diabe-
tes with deafness (MIDD). MIDD results from the sequence
differences of the mitochondrial genome and the severity of
the diabetic phenotype may vary, from mild hyperglycemia
to insulin dependence [42, 43]. The subsequent step of
glucose sensing mechanism, the ATP-sensitive potassium
channel consists of 2 subunits: channel-building Kir6.2,
encoded by the KCNJ11 gene, and regulatory SUR1,
encoded by the ABCC8 gene [44]. Activating mutations of
either of these genes, keeping the channel in open confor-
mation result in a diabetic phenotype, most commonly
PNDM, less frequently MODY or relapsing diabetes [11,
44, 45]. Since KCNJ11 is expressed outside the pancreas,
some mutation carriers, in addition to insulin-dependent
diabetes, present with neurological features such as devel-
opmental delay and muscle weakness [11, 44].
Beta cells may fail to produce and store a sufficient
amount of fully functional hormone in their secretory gran-
ules. This happens when the INS gene coding for their
content, insulin, is affected [46]. The defective and abnor-
mally folded proinsulin molecule may induce the unfolded
protein response and undergo degradation in the endoplas-
mic reticulum. It has been hypothesized that the resulting
endoplasmic reticulum stress leads to beta cell apoptosis.
The range of phenotypes varies from some mutations result-
ing in a complete destruction of beta cells and absolute lack
of insulin and PNDM to others producing a MODY-like
phenotype [47].
One of the most common causes of monogenic diabetes
are sequence differences of genes encoding transcription
factors. Their pathology is associated with impaired growth,
differentiation and renewing of beta cells, as well as with an
impaired transcription of the insulin gene. Transcription
factor autosomal dominant mutations result in MODY. The
genes that code for transcription factors associated with
monogenic diabetes include HNF1A, HBF1B, HNF4A,
PDX1, NEUROD1, and some others [15–19]. These tran-
scription factors show varying expression patterns at differ-
ent stages of pancreas development [48]. Selected genes and
pathways of insulin secretion affected by monogenic dis-
eases are shown in Table 3.
Monogenic defects producing insulin resistance, the oth-
er fundamental component of the T2DM phenotype, seem to
be less explored than single gene defects of insulin secre-
tion. Nevertheless, a few examples of pathophysiological
models are also available for severely impaired insulin ac-
tion. Insulin receptor gene (INSR) mutations are linked to
several syndromes of generalized insulin resistance. Their
clinical presentation may be severe, with short stature, dys-
morphic features, and short life expectancy, as in Donohue
syndrome and Rabson-Mendenhall syndrome [49, 50].
These syndromes result from homozygous or compound
heterozygous mutations [51, 52]. A milder form linked to
the insulin receptor gene is type A insulin resistance, which
may have dominant or recessive inheritance [53]. The
patients may have less pronounced features present in pedi-
atric syndromes, such as enlarged chin, nose, ears, and
dental abnormalities. More importantly, phenotypic charac-
teristics of INSR mutations include, in addition to hypergly-
cemia, other clinical features observed in T2DM and
associated disorders, such as acanthosis nigricans, hirsutism,
and polycystic ovaries. Mutations in the AKT2 gene, coding
for kinase, which plays a central role in post-receptor insulin
signaling, produce insulin resistant diabetes and elevated
fasting triglycerides, low HDL cholesterol, and high LDL
level, a presentation similar to dyslipidemia accompanying
T2DM. Patients also have liver steatosis, resembling the
non-alcoholic fatty liver disease in T2DM [54]. AKT2 mu-
tation carriers also have reduced adipose tissue content.
Congenital partial lipodystrophies resulting from mutations
in LMNA, coding for nuclear envelope components, lamin A
and C, or from mutations in gene coding the peroxisome
proliferator activated receptor γ (PPARG) are characterized
by abnormalities in the lipid profile (hypertriglyceridemia,
low HDL-cholesterol), hirsutism, acanthosis nigricans, and
hypertension [55, 56]. In these disorders we observe abnor-
mal body fat distribution, which emphases the role of fat
metabolism in the pathogenesis of insulin resistance.
In summary, it is quite clear that exploring monogenic
diabetes provided new insights to a better understanding
of the pathophysiological events leading to chronic
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hyperglycemia not only in single gene diabetes but also in
complex forms of this disease.
Pharmacogenetics in Diabetes
Another lesson coming from monogenic models of diabetes
is that hypoglycemic treatment may be tailored for some
patients based on the etiology of their diseases, which con-
stitutes an example of pharmacogenetics. Pharmacogenetics
is a scientific discipline that examines genetic variations that
gives rise to differing response to drugs. This includes not
only therapeutic efficacy but also toxic side effects of drugs.
Probably the earliest of pharmacogenetics is related to
HNF1A MODY [7, 8, 16]. In this monogenic diabetes,
pharmacologic treatment is usually inevitable; however, in
spite of a frequently young age of diabetes onset, one can
use a treatment alternative to insulin. Since sulfonylureas
(SU), the oldest group of oral hypoglycemic agents, act on
the beta cell and enhance insulin secretion [57], the notion
that the latter group are the drugs of choice in MODY was
very appealing. Several case reports from various popula-
tions suggested that patients with HNF1A MODY were
characterized by a specifically prominent therapeutic re-
sponse to SU [58, 59]. This hypothesis was eventually
confirmed by a double blind, randomized, clinical study that
compared the efficacy of gliclazide and metformin in
HNF1A MODY and complex T2DM [60••]. HNF1A
MODYpatients showed much a better response to gliclazide
than the patients with T2DM and this difference was asso-
ciated with a great insulin secretion improvement in MODY
patients. The effect of metformin on glucose levels in
MODY patients was much weaker than for SU. The
researchers attributed the findings to the nature of the beta
cell defect in MODY, as HNF1A is responsible for the
expression of genes involved in glucose uptake, glycolysis,
and mitochondrial metabolism. SU act downstream to these
cellular defects by binding to the SUR1 subunit of the ATP-
dependent potassium channel [57]. Thus, they are able to
overcome the defects underlying this genetic form of diabe-
tes and improve beta cell functioning. Thus, the genetic
cause of HNF1A MODY is an important determinant of
the response to oral hypoglycemic drugs. To date, the study
of Pearson et al is the only randomized clinical trial per-
formed in a monogenic population. The pathophysiological
similarity suggests that SU are efficient in other MODY
forms linked to transcription factors [7, 8, 15, 17–19, 61].
Unlike in transcription factor monogenic diabetes, in GCK
MODY diet is sufficient in most affected subjects [7, 8, 62].
In some individuals affected by MIDD, the disease close-
ly mimics T1DM and it requires insulin from the very
diagnosis. In many other cases, secretagogues or even a diet
alone are sufficient, at least for some time [63]. Metformin is
generally considered contraindicated in MIDD patients be-
cause of the potential risk for lactate acidosis. However, this
notion is based solely on the knowledge of the MIDD
pathophysiology and biguanides mode of action rather than
on clinical data.
Another spectacular example of tailoring hypoglycemic
treatment to disease etiology is PNDM. Patients with
KCNJ11 mutations are characterized by a very good re-
sponse to SU treatment. In this form of KCNJ11-related
PNDM, SU action precisely corrects the mechanism under-
lying this type of diabetes by closing the activated potassi-
um channel of the beta cells [11, 35, 64]. Successful transfer
from insulin to SU has been accomplished for both adults
and children, including infants [11, 65, 66, 67••, 68, 69]. In
most of these cases, a substantial improvement in glycemic
control was seen and no major side effects were reported.
The doses of various SU compounds were much higher than
usually therapeutically used in T2DM. It was hypothesized
that SU use might be particularly useful in the correction of
Table 3 Monogenic defects of
insulin secretion Genes Function of the protein or tRNA Phenotype of mutation
carriers
HNF1A, HNF1B, HNF4A, PDX1,
NEUROD1, KLF11, PAX4
Involvement in beta cell differentiation,
proliferation and insulin synthesis
MODY, rarely PNDM if
biallelic dysfunction
BLK Non-receptor tyrosine-kinase regulat-
ing insulin synthesis
MODY
SLC2A2 (GLUT2) Glucose transport to beta cell Fanconi-Bickel
syndrome
GCK Glucose phosphorylation in the limiting
step of ATP production in beta cell
MODY, PNDM if
biallelic dysfunction
mitochondrial leucyl tRNA gene and
several other mitochondrial genes
Mitochondrial ATP synthesis MIDD
KCNJ1, ABCC8 Structure and function of the ATP-
sensitive potassium channel of beta
cells
PNDM, TNDM, MODY
INS Coding for insulin PNDM, MODY
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some extra-pancreatic symptoms, such as muscle weakness,
or developmental delay. Indeed, recently published data
provided evidence for neurological improvement in diabetic
Kir6.2 mutation carriers after glibenclamide use [70]. In
addition, most of the patients with a molecular diagnosis
of PNDM due to ABCC8 gene mutations could also be
transferred off from insulin to SU [11, 47]. Unfortunately,
we will not find such spectacular examples of pharmacoge-
netics for forms of diabetes associated with severe insulin
resistance and clinical management of these patients
remains challenging.
The important question that arises is whether we can
translate the therapeutic success from some monogenic
forms of diabetes to polygenic ones. Indeed, several com-
mon polymorphisms in genes linked to monogenic forms
seem to influence the response to pharmacological treat-
ment. The polymorphisms of KCNJ11 and TCF7L2 genes
were associated with a therapeutic efficacy of SU in patients
with T2DM [71, 72]. The ABCC8 gene (encoding SUR1)
Ser1369Ala variant was found to be associated with anti-
diabetic efficacy of gliclazide in the Asian population [73].
The Glu23Lys variant of KCNJ11 was also associated with
risk for severe SU-induced hypoglycemia in T2DM patients
[74]. In a patch-clamp technique based study aimed to
analyze nucleotide sensitivity and SU inhibition of recom-
binant human KATP channels containing KCNJ11/ABCC8
variants, the increased sensitivity of the Glu23/Ala1369
variant combination to the SU-gliclazide was found [75].
However, realistically, we should not expect that in the
nearest future pharmacological treatment in T2DM will be
based on genetic testing. This stems from the fact that the
response to treatment is probably influenced by many var-
iants, each of them having little effect on the drug efficacy. It
is possible that future discoveries of rare, major effect var-
iants may add new perspectives for pharmacogenetics in
T2DM.
Conclusions
There are several lessons that we have learned from the
monogenic diabetes research. The success in dissecting the
molecular cause of rare diabetes forms encouraged and
inspired genetic research of complex diabetes. The identifi-
cation of new pathophysiological pathways for single gene
diabetes enabled a better understanding of T2DM mecha-
nisms. Spectacular pharmacogenetics examples in MODY
and PNDM give us hope that, sometime in the future,
hypoglycemic drugs will be tailored for other forms of
diabetes based on their etiologies. Moreover, it seems that
there is still some potential in exploring the role of genes in
which mutations cause monogenic diabetes in polygenic
forms of the disease. The application of novel technologies,
including exome sequencing, may be useful. It may happen
that the same new technology will be used for the search for
novel mutations responsible for monogenic diabetes and
“oligogenes” for common types of the disease. There is also
a hope that new drugs targeting proteins and pathways
altered in some forms of monogenic diabetes will be
developed.
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